JPWO2020139525A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020139525A5 JPWO2020139525A5 JP2021537848A JP2021537848A JPWO2020139525A5 JP WO2020139525 A5 JPWO2020139525 A5 JP WO2020139525A5 JP 2021537848 A JP2021537848 A JP 2021537848A JP 2021537848 A JP2021537848 A JP 2021537848A JP WO2020139525 A5 JPWO2020139525 A5 JP WO2020139525A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- betamethasone
- weight
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 229960000951 mycophenolic acid Drugs 0.000 claims description 7
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 7
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
- 229960005354 betamethasone sodium phosphate Drugs 0.000 claims description 4
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 claims description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000023715 Ocular surface disease Diseases 0.000 claims 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 4
- 229960002537 betamethasone Drugs 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 229960004648 betamethasone acetate Drugs 0.000 claims 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims 1
- 229960001102 betamethasone dipropionate Drugs 0.000 claims 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims 1
- 229960004311 betamethasone valerate Drugs 0.000 claims 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004175 meibomian gland Anatomy 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785312P | 2018-12-27 | 2018-12-27 | |
| US62/785,312 | 2018-12-27 | ||
| PCT/US2019/064371 WO2020139525A1 (en) | 2018-12-27 | 2019-12-04 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516099A JP2022516099A (ja) | 2022-02-24 |
| JP2022516099A5 JP2022516099A5 (https=) | 2022-12-12 |
| JPWO2020139525A5 true JPWO2020139525A5 (https=) | 2022-12-12 |
Family
ID=71127864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537848A Pending JP2022516099A (ja) | 2018-12-27 | 2019-12-04 | 眼科用医薬組成物及び癌表面疾患の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12070442B2 (https=) |
| EP (1) | EP3902525A4 (https=) |
| JP (1) | JP2022516099A (https=) |
| KR (1) | KR20210141448A (https=) |
| CN (1) | CN113473970A (https=) |
| AU (1) | AU2019417161B2 (https=) |
| BR (1) | BR112021012492A2 (https=) |
| CA (1) | CA3124945A1 (https=) |
| IL (1) | IL284344A (https=) |
| MX (1) | MX2021007709A (https=) |
| SG (1) | SG11202106967QA (https=) |
| WO (1) | WO2020139525A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7138103B2 (ja) | 2016-11-29 | 2022-09-15 | オキュリス エスエー | 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造 |
| WO2019060696A1 (en) * | 2017-09-25 | 2019-03-28 | Surface Pharmaceuticals, Inc. | OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE |
| WO2022076398A1 (en) * | 2020-10-07 | 2022-04-14 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| CA3124945A1 (en) | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| EP4670738A3 (en) | 2019-07-01 | 2026-03-04 | Oculis Operations Sàrl | Method for stabilizing the ph of an aqueous composition comprising a drug |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12310981B2 (en) | 2021-05-10 | 2025-05-27 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| EP4469059A4 (en) * | 2022-01-24 | 2026-01-21 | Surface Ophthalmics Inc | PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF EYE DISORDERS |
| JP2025538061A (ja) | 2022-11-04 | 2025-11-26 | クラリス バイオ インコーポレイテッド | クロマカリムの局所眼内送達 |
| EP4616843A1 (en) * | 2024-03-13 | 2025-09-17 | Iakov Mirkin | Pharmaceutical composition for use in the treatment of ulcerative colitis and in the treatment of interstitial cystitis/bladder pain syndrome |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2503563A1 (fr) | 1981-04-09 | 1982-10-15 | Pos Lab | Composition pour collyre a base de sulfate de chondroitine a |
| US4863907A (en) | 1984-06-29 | 1989-09-05 | Seikagaku Kogyo Co., Ltd. | Crosslinked glycosaminoglycans and their use |
| US4696917A (en) | 1985-08-01 | 1987-09-29 | Lindstrom Richard L | Irrigation solution |
| CA2041828A1 (en) | 1990-03-05 | 1992-11-04 | Richard L. Lindstrom | Viscoelastic solution |
| US5514686A (en) | 1991-04-26 | 1996-05-07 | Fujisawa Pharmaceutical Co., Ltd. | Use of macrolide compounds for eye diseases |
| US5518732A (en) | 1995-02-14 | 1996-05-21 | Chiron Vision, Inc. | Bio-erodible ophthalmic shield |
| US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| AU777915B2 (en) | 1999-04-30 | 2004-11-04 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| US6489335B2 (en) | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| EP1142566B1 (fr) * | 2000-04-07 | 2003-10-01 | Laboratoire Medidom S.A. | Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate |
| CN1127955C (zh) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
| DE10045343B4 (de) | 2000-09-14 | 2005-05-12 | Neuhann, Tobias, Dr.med. | Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels |
| AU2002230504A1 (en) | 2000-12-20 | 2002-07-01 | Alcon Universal Ltd. | Ophthalmic irrigating solution adapted for use in lasik surgery |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| GB0404693D0 (en) | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| WO2006044155A2 (en) | 2004-10-01 | 2006-04-27 | Lindstrom Richard L | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same |
| EP1814518A1 (en) | 2004-11-23 | 2007-08-08 | Alcon Inc. | Triple natural polymer viscoelastic composition |
| US20060148686A1 (en) * | 2004-12-30 | 2006-07-06 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| US20070082841A1 (en) | 2005-09-27 | 2007-04-12 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| DE102005055275A1 (de) | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
| WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| WO2007130364A2 (en) | 2006-05-01 | 2007-11-15 | Riolan Technologies, Inc. | Compositions, methods, and kits for treating dry eye |
| US20080242646A1 (en) | 2007-03-26 | 2008-10-02 | Lessem Jan N | Split dose corticosteroid therapy |
| JP5202986B2 (ja) | 2007-09-14 | 2013-06-05 | ロート製薬株式会社 | コンタクトレンズ装着液 |
| WO2009035033A1 (ja) | 2007-09-14 | 2009-03-19 | Rohto Pharmaceutical Co., Ltd. | 眼科用組成物 |
| JP2011505409A (ja) | 2007-12-04 | 2011-02-24 | ノバガリ ファーマ エスエー | パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物 |
| US20100010082A1 (en) | 2008-07-09 | 2010-01-14 | Aspreva International Ltd. | Formulations for treating eye disorders |
| US10201548B2 (en) | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| US10980818B2 (en) | 2009-03-06 | 2021-04-20 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| JP5595206B2 (ja) | 2009-09-30 | 2014-09-24 | ロート製薬株式会社 | 眼科用液体組成物 |
| EP2308468A1 (en) | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| US20120264852A1 (en) | 2009-10-29 | 2012-10-18 | Colorado State University Research Foundation | Polymeric materials including a glycosaminoglycan networked with a polyolefin-containing polymer |
| FR2962044B1 (fr) | 2010-04-21 | 2013-02-22 | Horus Pharma | Emulsion lacrymimetique |
| US9233123B1 (en) | 2010-12-07 | 2016-01-12 | Richard L. Lindstrom | Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan |
| JP5925188B2 (ja) | 2011-04-08 | 2016-05-25 | ナノシータ株式会社 | 医薬製剤 |
| DK2797601T3 (en) * | 2012-02-10 | 2018-06-14 | Taiwan Liposome Co Ltd | PHARMACEUTICAL COMPOSITIONS FOR REDUCING COMPLICATIONS BY Ocular steroid |
| US9549966B2 (en) | 2012-02-21 | 2017-01-24 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| ITPD20120098A1 (it) | 2012-03-30 | 2013-10-01 | Fidia Farmaceutici | "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico" |
| ITMI20120896A1 (it) | 2012-05-23 | 2013-11-24 | Bongulielmi Reto | Condroitina per uso in medicina |
| JP6452283B2 (ja) | 2012-11-06 | 2019-01-16 | ロート製薬株式会社 | 眼の異物感改善剤 |
| EP2916827B1 (en) * | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| EP2937088B1 (en) | 2012-12-21 | 2020-11-18 | Tokushima University | Composition having tissue repairing activity and utilization thereof |
| WO2015005458A1 (ja) | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
| US20150100348A1 (en) | 2013-10-08 | 2015-04-09 | Ims Health Incorporated | Secure Method for Health Record Transmission to Emergency Service Personnel |
| EP2979689A1 (en) | 2014-07-29 | 2016-02-03 | Sygene Technologies | Composition for an eye drop and delivery system therefor |
| JP2016050181A (ja) * | 2014-08-29 | 2016-04-11 | 大日本住友製薬株式会社 | 血管炎治療剤 |
| ES2938482T3 (es) | 2015-01-16 | 2023-04-11 | Seikagaku Kogyo Co Ltd | Sulfato de condroitina reticulado, composición que contiene el mismo y agente de tratamiento para enfermedad ocular |
| TWI773641B (zh) | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑 |
| US9789080B2 (en) * | 2015-09-04 | 2017-10-17 | Insite Vision Incorporated | Ophthalmic formulations of mycophenolic acid |
| US20190008891A1 (en) | 2016-01-29 | 2019-01-10 | Seikagaku Corporation | Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid |
| JP7288289B2 (ja) | 2016-11-11 | 2023-06-07 | ロート製薬株式会社 | 水性眼科組成物 |
| KR20190095937A (ko) | 2016-12-11 | 2019-08-16 | 시너지 더마톨로지 리미티드 | 설페이트화된 다당류를 포함하는 조성물 |
| EP3558308A1 (en) | 2016-12-22 | 2019-10-30 | Novaliq GmbH | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| US20190008920A1 (en) | 2017-05-19 | 2019-01-10 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| EP3624773A4 (en) * | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | OPHTHALMIC COMPOSITIONS AND METHOD OF USE |
| US20220143075A1 (en) | 2017-09-25 | 2022-05-12 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| WO2019060696A1 (en) * | 2017-09-25 | 2019-03-28 | Surface Pharmaceuticals, Inc. | OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE |
| US20230277557A1 (en) | 2017-09-25 | 2023-09-07 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| JP7104553B2 (ja) | 2018-03-30 | 2022-07-21 | ロート製薬株式会社 | 眼科組成物 |
| JP7417365B2 (ja) | 2018-05-09 | 2024-01-18 | ロート製薬株式会社 | 水性眼科組成物 |
| TW202547536A (zh) | 2018-05-09 | 2025-12-16 | 日商樂敦製藥股份有限公司 | 眼科組成物 |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| CA3124945A1 (en) | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| JP6866412B2 (ja) | 2019-02-28 | 2021-04-28 | 株式会社伊勢半 | 油中水型乳化化粧料 |
| JP7758466B2 (ja) | 2019-11-07 | 2025-10-22 | ロート製薬株式会社 | 眼科組成物 |
| US20230061058A1 (en) | 2020-02-14 | 2023-03-02 | Industry-Academic Cooperation Foundation, Yonsei University | Hydrogel of chondroitin sulfate functionalized with phenol derivative and use thereof |
| JP2022157707A (ja) | 2021-03-31 | 2022-10-14 | ロート製薬株式会社 | 眼科組成物 |
| WO2022240589A1 (en) | 2021-05-12 | 2022-11-17 | Schlumberger Technology Corporation | Autonomous inflow control device system and method |
| EP4469059A4 (en) | 2022-01-24 | 2026-01-21 | Surface Ophthalmics Inc | PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF EYE DISORDERS |
-
2019
- 2019-12-04 CA CA3124945A patent/CA3124945A1/en active Pending
- 2019-12-04 US US17/418,813 patent/US12070442B2/en active Active
- 2019-12-04 SG SG11202106967QA patent/SG11202106967QA/en unknown
- 2019-12-04 WO PCT/US2019/064371 patent/WO2020139525A1/en not_active Ceased
- 2019-12-04 EP EP19902055.3A patent/EP3902525A4/en active Pending
- 2019-12-04 AU AU2019417161A patent/AU2019417161B2/en not_active Ceased
- 2019-12-04 BR BR112021012492-6A patent/BR112021012492A2/pt not_active Application Discontinuation
- 2019-12-04 KR KR1020217023758A patent/KR20210141448A/ko not_active Withdrawn
- 2019-12-04 CN CN201980092852.9A patent/CN113473970A/zh active Pending
- 2019-12-04 MX MX2021007709A patent/MX2021007709A/es unknown
- 2019-12-04 JP JP2021537848A patent/JP2022516099A/ja active Pending
-
2021
- 2021-06-24 IL IL284344A patent/IL284344A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6886502B2 (ja) | アトロピン含有水性組成物 | |
| CN107865821B (zh) | 一种预防或治疗脉络膜新生血管形成的制剂 | |
| JP5524438B2 (ja) | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 | |
| AU738413B2 (en) | Human growth hormone-containing aqueous pharmaceutical composition | |
| JPWO2020139525A5 (https=) | ||
| CN102014920B (zh) | 滴眼剂制剂及其应用 | |
| JP2011093923A (ja) | 点眼剤 | |
| JPWO1999036065A1 (ja) | 医薬組成物 | |
| JPH08291065A (ja) | 有機アミンを配合したプラノプロフェン点眼液 | |
| JP4757970B2 (ja) | 点眼剤組成物 | |
| JPH0222223A (ja) | 医薬組成物 | |
| US4328213A (en) | Stable injectable labetalol formulation | |
| WO2021049963A1 (en) | Pharmaceutical composition of bimatoprost and timolol | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| JPH10338638A (ja) | 損傷皮膚修復用製剤 | |
| WO1993023032A1 (fr) | Remede contre la cataracte et procede de production associe | |
| US5093348A (en) | Pharmaceutical composition for topical ophthalmic use having improved local tolerability | |
| JP7723851B1 (ja) | アトロピン含有水性医薬組成物 | |
| CN113577020B (zh) | 一种玻璃体腔内注射剂、其制备方法及应用 | |
| JPH04261117A (ja) | グリチルリチン坐剤 | |
| CZ847488A3 (en) | Process for preparing cyclosporin a | |
| JPWO2023021492A5 (https=) | ||
| JPH06172181A (ja) | 脈絡膜血流量増加剤 | |
| JPWO1997041864A1 (ja) | 眼科用剤 | |
| JPWO2021142360A5 (https=) |